Steatohepatitis/Metabolic Liver Disease News

PHILADELPHIA — Endoscopic ultrasound-guided liver biopsy using three fanning needle motions provided superior tissue yields than a single needle throw, according to a presentation at the American College of Gastroenterology Annual Meeting.

PHILADELPHIA – Nonalcoholic fatty liver disease may have a “bidirectional” nature in patients with type 2 diabetes as NAFLD regressed in 2.2% of patients without any NAFLD-specific interventions despite increase in the prevalence of risk factors, according to a presentation at the American College of Gastroenterology Annual Meeting.

PHILADELPHIA — Early detection of liver-related complications and hepatic diseases in patients who are pregnant leads to reduced risks and improved outcomes for both mother and child, according to a presentation at the American College of Gastroenterology Annual Meeting.

Oramed Pharmaceuticals enrolled the first patient in an exploratory clinical study of ORMD-0801, an oral insulin capsule designed for the treatment of nonalcoholic steatohepatitis, according to a press release.

Liver stiffness measurements by magnetic resonance elastography and magnetic resonance imaging-proton density fat fraction demonstrated continued feasibility as biomarkers of liver fibrosis in a recently published study.

Hepatic encephalopathy is one possible outcome of chronic liver diseases such as cirrhosis and hepatitis and results in forgetfulness, disorientation, and even movement problems. Grading hepatic encephalopathy is key to guiding care among these patients.

The MoCA-CFS composite score — developed using the Montreal Cognitive Assessment and the Clinical Frailty Scale — independently predicted hospital admissions for hepatic encephalopathy and impaired health-related quality of life among patients with cirrhosis, according to recently published data.

Dova Pharmaceuticals and Salix Pharmaceuticals entered into an exclusive agreement to promote Doptelet, according to a press release.

Alnylam Pharmaceuticals announced positive topline results from an interim analysis of the Envision phase 3 study of givosiran, an RNA interference therapeutic designed to target aminolevulinic acid synthase 1, for the treatment of acute hepatic porphyria, according to a company press release and conference call.

Details from a recently published review discussed expanded use of alcohol use disorder medications and treatments in everyday clinical practice for patients with advanced liver disease.